Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Another market introduction for Lilly's SERM for postmenopausal women

Dec. 1, 1998

One Alkermes-R.W. Johnson collaboration makes progress, while another is terminated

Dec. 1, 1998

SB submits novel type II diabetes Rx for FDA approval

Dec. 1, 1998

FDA completes review of BioTime's NDA for Hextend

Dec. 1, 1998

Lilly describes use of dihydrobenzo[b]indenothiophenes for estrogen-related pathologies

Dec. 1, 1998

Australian team demonstrates safety of diabetes vaccine in patients

Nov. 30, 1998

Fujisawa discovers V-ATPase inhibitor with potential for treating osteoporosis

Nov. 30, 1998

Banyu reports success in the search for new ACAT inhibitors

Nov. 30, 1998

TAK-778: candidate for development in the treatment of osteoporosis

Nov. 30, 1998

New market introductions for raloxifene

Nov. 30, 1998

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...